Thus, PR is sufficient to induce tumor cell proliferation, invasion, and metastasis when ER signaling is abrogated, making it an attractive potential target for therapeutic intervention, particularly in endocrine-resistant diseases. The gene discussed is ESR1; the disease is neoplasm.